



Hormonal disorders changes in women suffering from polycystic ovary syndrome

Dalal F. Muhsin¹, Faris S. Kata¹, Edwar Z. Khosho²

¹Biology Department, College of Education of Pure Science, University of Basrah, Iraq

²Gynecology and Obstetrics Department, College of Medicine, University of Basrah, Iraq

Key words: Polycystic ovary syndrome, PCOS, Testosterone, Insulin, Cortisol

<http://dx.doi.org/10.12692/ijb/14.4.248-254>

Article published on April 15, 2019

Abstract

Polycystic ovary syndrome (PCOS) is one of the most common causes of infertility in reproductive age women around the world and it is identified as hyperandrogenism and chronic anovulation disorder. Because of the great number of women infected by PCOS in Iraq and in Basrah governorate in particular, and due to the increased rates of infertility and miscarriage cases related to PCOS, the current study has been designed to highlight some of the causes of PCOS through the changes in hormonal parameters. This study was done in basrah governorate since May, 2018 until November, 2018, serum samples were collected from (75) PCOS patients and (75) healthy women as control during the luteal phase of the menstrual cycle. Then the concentrations of (estradiol and progesterone, prolactin, testosterone, LH, TSH, T₃, insulin, cortisol, FSH and T₄) hormones were measured by using specific ELIZA kits. The results of our study showed that estradiol and progesterone were significantly decreased in PCOS patients than control group ($P < 0.05$), while prolactin, testosterone, LH, TSH, T₃, insulin and cortisol were significantly increased in PCOS patients than control group ($P < 0.05$), but our results showed no differences in the levels of serum FSH and T₄ hormones between PCOS patients and controls group ($P > 0.05$). In conclusion, the hormonal abnormalities are a characteristic trait in PCOS patients comparing with healthy women with normal hormones and this differences may be play an key role in the origins of PCOS in Basrah women and gives an overview about the causes of the prevalence of this disorder among these women.

*Corresponding Author: Dalal F. Muhsin ✉ dfalah14@gmail.com

Introduction

Polycystic ovarian syndrome (PCOS), also known as Stein–Leventhal Syndrome, is one of the most common endocrine disorder in a reproductive age women around the world (Azziz *et al.*, 2011; Singh *et al.*, 2018). A uniform definition of PCOS does not exist because of its diverse and heterogeneous nature, however PCOS is an endocrinopathy and should be referred as a syndrome rather than a disease (Lobo, 1995). PCOS was described at first time in 1935 by American gynaecologist's Stein and Leventhal in seven women suffer from oligomenorrhea, PCO, obesity hirsutism and acne (Chang *et al.*, 2002).

PCOS is characterized by menstrual irregularity, signs of hyperandrogenism like (excess body hairs, acne male-pattern baldness and infertility) also linked to several long term health risks such as central obesity, dyslipidemia, insulin resistance, type 2 diabetes, hyperinsulinemia, hypertension, cardiovascular diseases and higher rate of early loss of pregnancy (McCance *et al.*, 2010; Chen and Shi, 2010). Whether PCOS is a primary or a secondary ovarian disease remains controversial, the PCOS biological hyperandrogenism can not define PCOS and it has been suggested that the crucial pathophysiological factor of PCOS is dysregulation of the relationship among pituitary, hypothalamus and ovary. However, PCOS also involves in intraovarian functional and morphological abnormalities (Dewailly, 2009).

Recently proposed that PCOS origins in fetal life, it is suggested that exposure to excess androgen, at any stage from fetal development of ovary to puberty leads to several PCOS characteristic features such as LH secretion abnormalities and insulin resistance. The PCOS phenotype development results from a genetic predisposition for the fetal ovary to androgen hypersecretion. It is unclear whether maternal environment influences the PCOS development in offspring and the maternal androgen surplus is improbable to affect the fetus due to the placenta presents a dynamic barrier but the metabolic disturbances during pregnancy could affect development of PCOS in fetus (Franks *et al.*, 2006).

A universal agreement among specialty society guidelines that diagnosis of PCOS must be based on the presence of two of the following three criteria at least: clinical or biological hyperandrogenism, chronic anovulation and PCOM also echographic diagnosis have been suggested (Carmina, 2004; Goodman *et al.*, 2015). In PCOS patients, the follicle development stops at early stage and ovulation is blocked. The immature follicles turn into cysts and multiple cycles leads to multiple cysts, These cysts are sacs filled with fluid in one or both ovaries and the ovary size enlarged in up to twice the size of normal ovary. In PCOS, eggs are not release due to the follicle development stops so the immature follicle becomes cyst and corpus luteum is either not formed (cyst formation) leading to decrease in progesterone, estrogen hormones and the menstruation delays or stops, or forms when some immature follicle develops normally (Chaudhary and Qamar, 2016).

Different morphological and histological studies of PCOS revealed a thickened tunica albuginea, hyperplasia in theca interna and cortical stroma with many of subcapsular follicles in several stages of atresia (Ehrman *et al.*, 1995). In PCOS, fluid filled sacs grow inside the ovary, these sacs are follicles with immature eggs that never matured to trigger the ovulation which causes hormone imbalances like low levels of estrogen and progesterone with high androgen levels (Pasquali, 2018). Oligomenorrhea in PCOS women found to be associated with epithelial ovarian cancer, while women with irregular menstrual showed a decreased level of many of epithelial ovarian cancer histotypes (Harris *et al.*, 2018).

PCOS and endometrial hyperplasia which is a precancerous condition arises in the presence of chronic exposure to estrogen unopposed by progesterone such as in obesity and PCOS are associated with increased risk of endometrial carcinoma (Charalampakis *et al.*, 2016). The high levels of LH concentrations in PCOS during the follicular phase have a deleterious effect and may lead to early pregnancy loss so these women do not respond completely to LH treatment (Homburg *et al.*, 2016).

It is found that abnormalities in the endometrium of PCOS patients like an increased androgen receptors has a minor effect on fertility and The fertilization rates and normal development of the embryo were lower in PCOS women than in those with regular menstrual cycles (Barnes *et al.*, 1996; Apparao *et al.*, 2008).

The dysfunctional bleeding in PCOS females and chronic unopposed estrogen associated with anovulation problems leading to endometrial hyperplasia and cancer, while heavy continual bleeding leads to anemia (Carmina and Lobo 1999). Because the increased rates of infertility and miscarriage cases related to PCOS, the current study has been designed to underscore some of the causes of PCOS through the abnormalities in hormonal parameters.

Material and methods

Subjects

This study was performed in basrah governorate from May, 2018 to November, 2018. The diagnoses of women with PCOS were evaluated by gynecologist doctor, sonographer and laboratory assessment from a private gynecological clinic. Required data were collected by using the questionnaire includes (age, marital status, home, social status, length and weight, number of births, previous abortion, previous ectopic pregnancy, previous molar pregnancy, oligomenorrhea, other disease, drugs, smoking). Current study included (150) females (75) PCOS patient group and (75) and healthy women (fertile, regular menstrual cycle, no signs of hyperandrogenism and chronic disease) as control group, both groups are age matched (14-45). PCOS patients and control women did not get any hormonal therapy and medications for last four months of sample collection.

Blood sampling

10 milliliters of venous blood samples from PCOS and control group were collected during the luteal phase in Gel/clot activator tubes and then left for a short time to form blood clot, then serum was separated by using centrifuge (3500 rpm-10 minutes) at room temperature. After that, the serum divided into 12 eppendorf tubes for PCOS patients and another 12

eppendorf tubes for control group. these tubes were kept frozen at (-20°C) in deep freezer until time of analysis with avoiding multiple freezing.

Hormonal assay

Hormones concentration of PCOS patients and control group were measured by ELISA kits and the absorbance was recorded by the ELISA reader (Mindray (MR-96A)). Sandwich ELISA method was used for measuring Insulin, Prolactin, Follicular Stimulating Hormone (FSH), Luteinizing Hormone (LH), (Monobind Inc.) kits, Thyroid-Stimulating Hormone (TSH) (Bioactiva diagnostic) kit, and were measured by using Sandwich ELISA. Competitive enzyme immunoassay was used for measuring Progesterone, Triiodothyronine (T₃), thyroxine (T₄) (Monobind Inc) kits, Estradiol (Bioactiva diagnostic), Testosterone (Demeditec Diagnostics) kit and cortisol (Human) kit. The procedure for estimation of each hormone in the serum of PCOS patients and control group was followed exactly as illustrated in the leaflet accompanying the kit and the optical density of these hormones were measured by using ELISA reader.

Statistical analysis

Statistical Analysis are performed using SPSS version 20 with $P < 0.05$ being considered statistically significant. Data are expressed as median \pm (minimum- maximum) and the difference in the levels of these markers between PCOS cases and control group evaluated by Mann-Whitney Test, Kruskal-Wallis Test and multivariate Anova.

Results and discussion

As shown in the Tables (1,2), the serum levels of estradiol and progesterone are significantly decreased in PCOS patients when compared to control group which have normal concentrations, while the serum levels of testosterone, prolactin and LH is significantly increased in PCOS patients compared to control group that have normal values, but the level of serum FSH hormone showed no statistical significant difference between PCOS patients and control group. The abnormalities of neuroendocrine in PCOS patients may increase GnRH pulse, which increases the incidence and pulse capacity of LH production

(Banaszewska *et al.*, 2003; Jones, *et al.*, 2015; Dumitrescu *et al.*, 2015) There is several evidences suggests that abnormal ovarian steroidogenesis through over expression of the CYP17 gene being

responsible for increased expression of the LH receptor and androgen biosynthesis, which lead the ovarian theca cells to be more sensitive to LH stimulation (Comim *et al.*, 2013).

Table 1. Comparison of serum ovary hormones between control group and PCOS patients. Values was expressed as (median (min- max)).

Ovary hormones	Control(n=75)	PCOS(n=75)
Estradiol(pg/ml)	122.51(37.51-400.01)	48.97(3.707-296.70)**
progesterone(ng/ml)	12.50(0.65-24-21)	1.08 (0.023-18.84)**
testosterone(ng/ml)	0.46(0.02-1.44)	0.91(0.20-8.98)**

*significant at the ($P \leq 0.05$)

**significant at the ($P \leq 0.01$)

Table 2. Comparison of serum pituitary hormones between control group and PCOS patients.

Pituitary hormones	Control(n=75)	PCOS(n=75)
Prolactin(ng/ml)	11.721(1.00-19.92)	25.40(4.64-83.30)**
LH(mIU/ml)	2.23(0.50-10.40)	19.24(4.76-83.50)**
FSH(mIU/ml)	6.40 (1.70-13.50)	4.81(2.39-55.52)

*significant at the ($P \leq 0.05$)

**significant at the ($P \leq 0.01$)

Ovarian theca cell hyperandrogenism in PCOS patients is a combination of androgen receptor mediated weakness in estradiol and progesterone negative feedback regulation of LH release. The excessive secretion of LH increased the speed of GnRH releasing from median eminence in the hypothalamus, stimulates the steroidogenesis in ovarian theca cell and increase secretion testosterone and androstenedione.

It was assumed that progesterone resistance related with speeding up in LH release. Increased LH levels following acute progesterone receptor blockage diminished the progesterone negative feedback. This dysregulation of LH release in PCOS impaired the feedback mechanism of the hypothalamic GnRH release in evocative of PCOS neuroendocrinopathy. (Abbott *et al.*, 2018).

Elevation of prolactin is caused by reduced dopamine in the tuberoinfundibular tract, Decompensated liver function leads to changing in entering the amino acids in to central nervous system. levels of blood aromatic amino acids increase leading to an increase in the synthesis of false neurotransmitters. These false neurotransmitters may inhibit the releasing of dopamine (Als-Nielsen *et al.*, 2003; Velissaris,2008;Karagiannis and Harsoulis 2005; Jha and Kannan, 2016).

As shown in Table 3, the serum level of insulin, cortisol, TSH and T3 are significantly increased in PCOS patients when compared to control group that have normal concentrations, but there is showed no statistical significant difference in the level of T4 between PCOS patients and control group. Insulin resistance preserves hyperandrogenemia directly, by acting on theca cells stimulating excessive androgen secretion. Insulin also acts as a co-gonadotropin which increasing the effect of LH on ovarian androgen production. In result, Both androgens and insulin inhibit the liver SHBG secretion, increasing free and bioactive androgen levels and making clinical androgen excess more worse. The effect of high LH level and low level SHBG in the liver, induce the increase in androgen secretion in the ovary. then follicle maturation and growth are suppressed (Spritzer, 2014).

The cysts in PCOS are follicles of immature eggs that never matured enough to trigger ovulation so the lack of ovulation causes hormone imbalances such as estrogen, and progesterone levels are low while LH and androgen levels are high, The presence of these cysts are thought to occur because of two abnormalities within the blood hyperandrogenism

and hyperinsulinemia. Hyperandrogenism has been argued to be the defining feature in the disease. Hyperandrogenism causes the egg follicles to be in an arrested state called atresia which inhibits the

maturation of the egg. Because the high levels of androgen, the ovary is unable to release an egg for ovulation which causes oligomenorrhea and or amenorrhea (Knisley, 2018).

Table 3. Comparison of serum metabolic hormones between control group and PCOS patients. Values was expressed as (median (min- max)).

Metabolic hormones	Control(n=75)	PCOS(n=75)
TSH (μU/ml)	1.32(0.12-3.70)	1.52(0.34-17.02)**
T3 (μg/dl)	0.93(0.13-1.93)	1.28(0.36-9.34)**
T4 (μg/dl)	7.84 (1.50-11.90)	7.74 (1.57-19.77)
Insulin(μU/ml)	4.53(0.74-109.11)	62.19(1.90-196.07)**
cortisol(ng/ml)	97.71(55.01-250.01)	321.23(17.45-670.140)**

*significant at the ($P \leq 0.05$)

**significant at the ($P \leq 0.01$)

Increased TSH levels in PCOS patients may be caused by the unopposed estrogen in PCOS patients that excites autoimmune reactions such as formation of thyroid peroxidase antibodies (Padalkar *et al.*, 2017). TSH was found to be positively correlated with testosterone and prolactin in PCOS patients (Chen *et al.*, 2017). The elevated TSH and T3 in PCOS patients may be association with the metabolic changes like insulin resistance, HDL and apolipoprotein A secretion (Yin *et al.*, 2017). The increasing in cortisol level may be occur by the activation of hypothalamic pituitary adrenal axis (Agardh *et al.*, 2003). Cortisol and ACTH levels were found to be higher in PCOS patients than in healthy women. Because overproduction in ACTH in adrenal gland stimulates the increased level of cortisol (Tsilchorozidou *et al.*, 2003).

Increased thyroid hormone increases the secretion of the majority other endocrine glands, it also increases the requirement of these hormones by tissues. Thyroid hormone found to be able to increase the rate of cortisol secretion by the adrenal glands by the inactivation of cortisol in the liver and this leads to feedback increase in adrenocorticotrophic hormone production by the anterior pituitary (Guyton and Hall 2006). A shown previously cortisol hormone in the current study was increased in PCOS patients. Which plays an important role to stimulate directly the insulin secretion or indirectly increases gluconeogenesis. This action stimulates β -cells of islets of Langerhans to secrete insulin. Increased secretion of cortisol and insulin for a long time leads to attrition of β -cells.

Cortisol also decreases the sensitivity of different tissues insulin receptors to the metabolic effects of insulin. Eventually, all these effects can lead to development the diabetes mellitus (Sembulingam and Sembulingam, 2012). High cortisol might contribute to the development of endometrial Insulin resistance by inhibiting the insulin signaling pathway through induction of phosphatase and tensin homolog deleted on chromosome ten expression in endometrial epithelial cells (Qi, *et al.*, 2018).

Acknowledgements

Special thanks to everyone who contributed to the completion of the research; the department of Biology in the faculty of education for pure, University of Basrah and the medical staff, who cooperated with me in everything related to practical research procedures.

References

- Abbott DH, Vepraskas SH, Horton TH, Terasawa E and Levine JE.** 2018. Accelerated Episodic Luteinizing Hormone Release Accompanies Blunted Progesterone Regulation in PCOS-like Female Rhesus Monkeys (Macaca Mulatta) Exposed to Testosterone during Early-to-Mid Gestation. *Neuroendocrinology* **107**, 133-146.
- Agardh EE, Ahlbom A, Andersson T, Efendic S, Grill V, Hallqvist J, Ostenson CG.** 2003. Work stress and low sense of coherence is associated with type 2 diabetes in middle-aged Swedish women. *Diabetes care* **26**, 719-724.

Als-Nielsen B, Koretz, RL, Kjaergard, LL, Gluud C. 2003. Branched-chain amino acids for hepatic encephalopathy. Cochrane Database of Systematic Reviews.

Apparao KB, Lovely LP, Gui Y, Lininger RA, Lessey BA. 2008. Elevated endometrial androgen receptor expression in women with polycystic ovarian syndrome. *Biology of Reproduction* **66**, 297-304.

Azziz R, Dumesic DA, Goodarzi MO. 2011. Polycystic ovary syndrome: an ancient disorder?. *Fertility and sterility* **95**, 1544-1548.

Banaszewska B, Spaczynski RZ, Pelesz M, Pawelczyk L. 2003. Incidence of elevated LH/FSH ratio in polycystic ovary syndrome women with normo- and hyperinsulinemia. *Roczniki Akademii Medycznej w Białymstoku* **48**, 131-134.

Barnes FL, Kausche A, Tiglias J, Wood C, Wilton L, Trounson A. 1996. Production of embryos from in vitro-matured primary human oocytes. *Fertility and sterility* **65**, 1151-1156.

Carmina E, Lobo RA. 1999. Polycystic ovary syndrome (PCOS, Arguably the most common endocrinopathy is associated with significant morbidity in women. *The Journal of Clinical Endocrinology and Metabolism* **84**, 1897-1899.

Carmina E. 2004. Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-ASRM guidelines. *Minerva Ginecologica* **56**, 1-6.

Chang RJ, Heindel J, Dunaif A. 2002. Polycystic ovary syndrome. New York, Marcel Dekker Inc 1-14.

Charalampakis V, Tahrani AA, Helmy A, Gupta JK and Singh R. 2016. Polycystic ovary syndrome and endometrial hyperplasia: an overview of the role of bariatric surgery in female fertility. *The European Journal of Obstetrics and Gynecology and Reproductive Biology* **207**, 220-226.

Chaudhary N, Qamar I. 2016. Polycystic Ovary Syndrome: Conditions. Genetics and Current Cure. *The Journal of Clinical Endocrinology and Metabolism* **3**, 2-7.

Chen L, Tan Y, Cao P. 2017. Relationship of thyroid stimulating hormone with sex hormones in patients with polycystic ovary syndrome: a single-center, retrospective observational study. *International Journal of Clinical and Experimental Pathology* **10**, 5989-5993.

Chen Z, Shi Y. 2010. Polycystic ovary syndrome. *Frontiers of medicine in China* **4**, 280-284.

Comim FV, Teerds K, Hardy K, Franks S. 2013. Increased protein expression of LHCG receptor and 17 α -hydroxylase/17-20-lyase in human polycystic ovaries. *Human Reproduction* **28**, 3086-3092.

Dewailly D. 2009. Definition of polycystic ovary syndrome. *Human Fertility* **3**, 73-76.

Dumitrescu R, Mehedintu C, Briceag I, Purcarea VL, Hudita D. 2015. The Polycystic Ovary Syndrome: An update on metabolic and hormonal mechanisms. *Journal of Medicine and Life* **8**, 142-145.

Ehrman DA, Barnes RB, Rosenfield RL. 1995. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. *Endocrine Reviews* **16**, 322-353.

Franks S, McCarthy MI, Hardy K. 2006. Development of polycystic ovary syndrome: involvement of genetic and environmental factors. *International Journal of Andrology* **29**, 278-285.

Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E. 2015. American association of clinical endocrinologists, american college of endocrinology and androgen excess and PCOS society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome - part 1. *Endocrine Practice* **21**, 1415-26.

Guyton AC, Hall JE. 2006. Textbook of Medical Physiology. 11th Edition, Elsevier Saunders, Amsterdam.

Hague WM, Millar DR. 1985. Excessive testosterone secretion in pregnancy. Case report. *British Journal of Obstetrics and Gynaecology* **92**, 173-178.

Harris HR, Babic A, Webb, PM, Nagle, CM, Jordan SJ, Risch HA, Ness RB. 2018. Polycystic ovary syndrome, oligomenorrhea, and risk of ovarian cancer histotypes: Evidence from the Ovarian Cancer Association Consortium. *Cancer Epidemiology and Prevention Biomarkers* **27**, 174-182.

Homburg R, Ray A, Bhide P, Gudi A, Shah A, Timms P, Grayson K. 2013. The relationship of serum anti-Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study, *Human Reproduction* **28**, 1077-1083.

Jha SK, Kannan S. 2016. Serum prolactin in patients with liver disease in comparison with healthy adults: A preliminary cross-sectional study. *International Journal of Applied and Basic Medical Research* **6**, 8-10.

Jones MR, Brower MA, Xu. N, Cui J, Mengesha E, Chen YDI, Goodarzi MO. 2015. Systems genetics reveals the functional context of PCOS loci and identifies genetic and molecular mechanisms of disease heterogeneity. *PLoS genetics* **11**, e1005455.

Karagiannis A, Harsoulis F. 2005. Gonadal dysfunction in systemic diseases. *European Society of Endocrinology* **152**, 501-13.

Knisley E. 2018. Polycystic Ovarian Syndrome. Master of Science in Nursing, Student Scholarship **327**.

Lobo RA. 1995. A disorder without identity "HCA," "PCO," "PCOD," "PCOS," "SLS." What are we to call it?. *Fertility and Sterility* **63**, 1158-60.

Mccance KL, Huether SE, Brashers VL, Rote NS. 2010. Pathophysiology: The Biologic Basics for Disease in Adults and Children. United States of America. Mosby Elsevier, 824-826.

Padalkar RK, Patil SM, Andure DV, Bhagat SS, Raut AM. 2017. Study of Hormone and Lipid Profile

in Polycystic Ovarian Syndrome Women between the Age 18 to 30 Years. *Journal of Practical Biochemistry and Biophysics* **2**, 11-15.

Pasquali R. 2018. Lifestyle Interventions and Natural and Assisted Reproduction in Patients with PCOS. In *Infertility in Women with Polycystic Ovary Syndrome*. Springer, Cham 169-180.

Qi J, Wang W, ZhuQ, HeY, Lu Y, Wang Y, Li X, Chen Z, Sun Y. 2018. Local Cortisol Elevation Contributes to Endometrial Insulin Resistance in Polycystic Ovary Syndrome. *The Journal of Clinical Endocrinology and Metabolism* **103**, 2457-2467.

Sembulingam K, Sembulingam P. 2012. Essential medical physiology. 6th Edition, Jaypee Brothers Medical Publishers, India.

Singh S, Ravichandran R, Panda PK. 2018. The enigma of PCOS. *Journal of RNA Genomics* **14**, 610-614.

Spritzer PM. 2014. Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances. *Arquivos Brasileiros de Endocrinologia and Metabologia* **58**, 182-187.

Tsilchorozidou T, Honour JW, Conway GS. 2003. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5 α -reduction but not the elevated adrenal steroid production rates. *The Journal of Clinical Endocrinology and Metabolism* **88**, 5907-5913.

Velissaris D, Karanikolas M, Kalogeropoulos A, Solomou E, Polychronopoulos P, Thomopoulos K. 2008. Pituitary hormone circadian rhythm alterations in cirrhosis patients with subclinical hepatic Encephalopathy. *The World Journal of Gastroenterology* **14**, 4190-4195.

Yin D, Ruan X, Tian X, Du J, Zhao Y, Cui Y, Mueck AO. 2017. The relationship between thyroid function and metabolic changes in Chinese women with polycystic ovary syndrome. *Gynecological Endocrinology* **33**, 332-335.

